Lung Cancer Biomarker Testing ECHO – Year 4
November 2024 - May 2025
Despite an unprecedented deployment of new effective treatment options for non-small cell lung cancer (NSCLC) that targets specific biomarkers, many patients face enormous challenges obtaining comprehensive biomarker testing. Participating health systems will gain the knowledge to address common barriers that exist within their cancer teams and institutions that preclude them from implementing NSCLC biomarker testing. This program will kick off in November of 2024, followed by six hour-long sessions between January and May 2025.